View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
February 11, 2020updated 12 Jul 2022 11:57am

Moderna enrols first patient in Phase I/II trial of mRNA-3704

Clinical-stage biotechnology firm Moderna has enrolled the first patient in the Phase I/II trial of mRNA-3704 in methylmalonic acidemia (MMA) patients.

Clinical-stage biotechnology firm Moderna has enrolled the first patient in the Phase I/II trial of mRNA-3704 in methylmalonic acidemia (MMA) patients.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

The mRNA-3704, which is the company’s first rare disease programme to enter clinical trials, will be administered through intravenous infusion in patients with isolated MMA due to mitochondrial enzyme methylmalonic-CoA mutase (MUT) deficiency.

The open-label study will evaluate the safety and tolerability of up to four mRNA-3704 ascending dose levels.

Moderna noted that the patients will take part in a pre-dosing observational period before moving to treatment period and a follow-up period after treatment withdrawal. the observational period helps analyse the patient’s baseline disease.

According to the company, the lipid nanoparticle (LNP) formulation used for mRNA-3704 is also used in Moderna’s chikungunya antibody programme (mRNA-1944) and propionic acidemia (mRNA-3927). Moderna’s chikungunya antibody programme has reported positive results for the interim Phase I study.

Moderna chief medical officer Tal Zaks said: “This study will provide important information about the potential of an mRNA approach to replace the deficient enzyme in patients with MMA, which currently has no approved medical therapy or investigational medicines that address the underlying cause.

“As the first of our rare disease programmes to begin clinical trial enrolment, we look forward to learning from the patients and families in our clinical trial as we investigate and advance an mRNA platform that may help treat this challenging condition.”

Moderna’s mRNA-3704 has received fast track, orphan drug, and rare paediatric disease designation from the US Food and Drug Administration (FDA).

The drug has also received orphan designation by the European Medicines Agency (EMA).

Moderna plans to start several sites outside the US. The company has secured approval from the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK so far.

In September 2019, Moderna reported positive interim results from the Phase I clinical trial of its mRNA-1647 prophylactic vaccine for cytomegalovirus (CMV).

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena